1. No category

Sunday 9th
16:00-18:00: Pre-Symposium: “Update in HPRT deficiency and Lesch-Nyhan
Disease” sponsored by The Lesch-Nyhan Disease Spanish Association. W.L. Nyhan
(USA), H. A. Jinnah (USA).
16:00-16:20: I-1: W. L. Nyhan (University of California San Diego, USA). LESCH-NYHAN
DISEASE HPRT DEFICIENCY AND RELATED DISORDERS OF PURINE METABOLISM.
16:20-16:40: I-2: H.A. Jinnah (Emory University, Department of Neurology, Atlanta, USA).
GENOTYPE-PHENOTYPE CORRELATIONS IN LESCH-NYHAN DISEASE AND ITS
ATTENUATED VARIANTS.
16:40 :17:00 : I-3: I. Ceballos-Picot (Laboratoire de Biochimie métabolomique et protéomique;
Laboratoire de Biostatistiques – Hôpital Necker/Université Paris Descartes, Paris, France).
GENETIC, METABOLOMIC AND TRANSCRIPTOMIC APPROACHES OF LESCHNYHAN DISEASE.
17:00-17:20: I-4: R.J. Torres and J.G. Puig (La Paz University Hospital, IdiPAZ, Madrid,
Spain). HPRT DEFICIENCY IN SPAIN: WHAT HAVE WE LEARNED IN THE PAST 30
YEARS (1984 – 2013)?
17:20-17:50: I-5: Spanish Lesch Nyhan Association and French Lesch Nyhan Association.
17:50-18:00: Discussion.
19:30-21:00; Welcome reception (Hotel Velazquez)
Monday 10th
08:30-10:30: Session 1: “Advances in gout and hyperuricemia”. M.A. Becker
(USA) and F. Pérez Ruiz (Spain).
08:30-09:00: I-6: M.A. Becker (The University of Chicago, Chicago Illinois, USA).
ADVANCES IN THE MEDICAL AND SCIENTIFIC UNDERSTANDING OF GOUT: 19732013.
09:00-09:20: O-1: F. Ottery (Savient Phramaceuticals, Inc, New Jersey, USA). PEGLOTICASE:
KEY EFFICACY AND SAFETY DATA PROVIDE BASIS FOR OPTIMAL
ADMINISTRATION.
09:20-09:45: O-2: T. Takada (Department of Pharmacy, The University of Tokyo Hospital,
Faculty of Medicine, The University of Tokyo, Japan). DYSFUNCTION OF A URATE
EXPORTER ABCG2 AS A MAJOR RISK FACTOR OF HYPERURICEMIA AND GOUT.
09:45-10:00: O-3: R. Bailen (Metabolic Vascular Unit, Internal Medicine, Hospital
Universitario la Paz, Madrid, Spain). EFFICACY AND SAFETY OF HYPOURICEMIC
REGIMEN IN PRIMARY GOUT.
10:00-10:30: I-7: F. Perez-Ruiz (Rheumatology Division, Cruces University Hospital and
BioCruces Health Institute, Spain). GOUT: A CONTINUUM FROM HYPERURICEMIA TO
STRUCTURAL DAMAGE.
10:30-11:00: Coffee Break.
11:00- 12:30: Session 2: “Inborn errors of Metabolism”. I. Sebesta (Czech
Republic) and R. J. Torres (Spain).
11:00-11:15: I-8: I Sebesta (Institute of Inherited Metabolic Disorders, First Faculty of
Medicine, Charles University,Prague, Czech Republic). HYPOURICEMIA AS A
DIAGNOSTIC TOOL.
11:15-11:30: I-9. B. Almoguera (Genetics Department, IIS-Fundación Jiménez Díaz, CIBERER,
Madrid, Spain) NOVEL MUTATION CAUSING PRPP SYNTHETASE DEFICIENCY:
GENOTYPE-PHENOTYPE CORRELATION IN FOUR AFFECTED WOMEN.
11:30-11:45: O-4: A. Van Kuilenburg (Laboratory of Genetic Metabolic Diseases, Academic
Medical Center, Amsterdam, Netherlands). ß-UREIDOPROPIONASE DEFICIENCY:
PHENOTYPE, GENOTYPE AND PROTEIN STRUCTURAL CONSEQUENCES.
11:45-12:00: O-5: M. Castro (Centro de Diagnóstico de Enfermedades Moleculares . CIBERER,
Universidad Autónoma de Madrid, Madrid, Spain). THIRTEEN YEARS EXPERIENCE WITH
SELECTIVE SCREENING FOR DISORDERS IN PURINE AND PYRIMIDINE
METABOLISM.
12:00-12:15: O-6: G. Bollée (Nephrology, Necker Hospital, Paris, France). ADENINE
PHOSPHORIBOSYLTRANSFERASE (APRT) DEFICIENCY : GENOTYPE AND
PHENOTYPE CHARACTERIZATION OF A LARGE COHORT.
12:15-12:30: O-7: L. Fairbanks (Purine Research Laboratory, GSTS Pathology, Guys' and
St.Thomas' Hospital, London, UK). HEREDITARY OROTIC ACIDURIA: IS ANAEMIA
ALWAYS PRESENT?
12:30:-13:30: Posters oral presentation session I: Presentation P1 to P16.
13:30-14:30. Lunch.
14:30-16:00: Session 3: “Purines, pyrimidines and Cancer”. G. J. Peters
(Netherlands) and C. M. Galmarini (Spain).
14:30-15:00: I-10: G.J. Peters (VU University Medical Centre, Amsterdam, Netherlands).
NOVEL DEVELOPMENTS IN THE USE OF ANTIMETABOLITES IN THE TREATMENT
OF CANCER.
15:00-15:15: O-8: D. Urbančič (Faculty of Pharmacy, University of Ljubljana, Ljubljana,
Slovenia). THIOPURINE METABOLISM: A CONNECTION BETWEEN TPMT ACTIVITY
AND FOLATE-METHIONINE CYCLE.
15:15-15:30: O-9: M Arenas (Purine Research Laboratory, GSTS Pathology, St. Thomas
Hospital, London, UK). GENETIC MARKERS ASSOCIATED WITH TOXICITY TO
FLUOROPYRIMIDINE THERAPY.
15:30-15:45: O-10: T. Yamauchi (First Department of Internal Medicine, University of Fukui,
Fukui, Japan). DEVELOPMENT OF A NEW T-LYMPHOBLASTIC LEUKEMIA CELL LINE
CCRF-CEM VARIANT RESISTANT TO NELARABINE.
15:45-16:00: O-11: A. Wojtuszkiewicz (VU University Medical Centre, Amsterdam,
Netherlands). 6MP METABOLITES AND 6MP METABOLIC KEY-ENZYMES AS
PREDICTIVE FACTORS ON CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA
(ALL).
16:00-16:30: Coffee Break
16:30-18:00: Poster oral presentation session II: Presentation P17 to P32.
19:00-22:00: Madrid Austria’s tour with TAPAS (optional).
Tuesday 11th
08:30-10:30: Session 4: “Nucleoside transporters and receptors”. M. Pastor
Anglada (Spain) and F. Ciruela (Spain).
08:30-09:00: I-11: F. Ciruela (Unitat de Farmacologia, Departament Patologia i Terapèutica
Experimental, Facultat de Medicina, IDIBELL-Universitat de Barcelona, L’Hospitalet de
Llobregat, Barcelona, Spain). PHOTOMODULATION OF THE G-PROTEIN COUPLED
ADENOSINE A2A RECEPTOR BY A NOVEL LIGHT-SWITCHABLE LIGAND.
09:00-09:15: O-12: A. Mediero (Division of Translational Medicine, Medicine Department,
NYU School of Medicine, New York, USA). ADENOSINE RECEPTORS STIMULATE BONE
REGENERATION BY TARGETING OSTEOCLASTS.
09:15-09:30: O-13; V. Fernández-Dueñas (Unitat de Farmacologia, Departament Patologia i
Terapèutica Experimental, Facultat de Medicina, IDIBELL-Universitat de Barcelona,
L’Hospitalet de Llobregat, Barcelona, Spain). ANTIPARKINSONIAN DRUGS AS NEGATIVE
MODULATORS OF THE ADENOSINE A2A RECEPTOR.
09:30-10:00: I-12. M. Pastor-Anglada (Department of Biochemistry and Molecular Biology,
Institute of Biomedicine, University of Barcelona (IBUB) and Oncology Program, National
Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD), Instituto
de Salud Carlos III, Spain). AN UPDATE ON NUCLEOSIDE TRANSPORTER BIOLOGY IN
HUMAN CELLS: IMPLICATIONS FOR CHEMOTHERAPY.
10:00-10:15: O-14: S. Pérez-Torras (Biochemistry and Molecular Biology, University of
Barcelona, CIBERehd, IBUB, Barcelona, Spain). CONCENTRATIVE NUCLEOSIDE
TRANSPORTER 1 (HCNT1) PROMOTES PHENOTYPIC CHANGES RELEVANT TO
TUMOR BIOLOGY IN A TRANSLOCATION–INDEPENDENT MANNER.
10:15-10:30: O-15: E. McKee (College of Medicine, Central Michigan University, Mt Pleasant,
MI, USA). MITOCHONDRIAL METABOLISM AND TRANSPORT OF
DEOXYPYRIMIDINE NUCLEOSIDES AND NUCLEOTIDES.
10:30-11:00: Coffee Break
11:00-12:30: Session 5: “Purine and pyrimidine enzyme regulation”. S. Eriksson
(Sweden) and R. I. Christopherson (Australia).
11:00-11:30: I-13: M. Webb (Genetic Medicine, University of Manchester, Manchester
Academic Heath Science Centre, Central Manchester Foundation Trust University Hospitals,
Manchester, UK). STRUCTURAL AND ENZYMOLOGICAL STUDIES OF THE HIV-1
RESTRICTION FACTOR, SAMHD1.
11:30-11:40: O-16: G. Pontarin (Department of Biology, University of Padova, Padova, Italy).
SAMHD1 REGULATES THE CATABOLISMS OF DNA PRECURSORS IN MAMMALIAN
CELLS.
11:40-12:00: I-14: R. Christopherson (School of Molecular Bioscience, University of Sydney,
Sidney, Australia). MECHANISMS OF ACTION OF FLUDARABINE NUCLEOSIDE
AGAINST HUMAN LYMPHOMA CELLS.
12:00-12:10: O-17: S. Ramón-Maiques (Structural Bases of Genome Integrity Group, Spanish
National Cancer Research Centre (CNIO), Madrid, Spain). TOWARDS DECIPHERING THE
3D STRUCTURE OF CAD, THE MASTERPIECE IN THE DE NOVO BIOSYNTHESIS OF
PYRIMIDINES.
12:10-12:20: O-18: V. Rao Jonna (Medical Biochemistry and Biophysics, Umeå University,
Umeå, Sweden). PSEUDOMONAS AERUGINOSA CLASS IA RIBONUCLEOTIDE
REDUCTASE REPRESENTS A NEW MECHANISM OF OVERALL ACTIVITY
REGULATION.
12:20-12 :30 : O-19 : R. Amsailale (de Duve Institute, Université Catholique de Louvain,
Brussels, Belgium). PHOSPHORYLATION OF DEOXYCYTIDINE KINASE ON SER-74:
IMPACT ON KINETIC PROPERTIES AND NUCLEOSIDE ANALOG ACTIVATION IN
CANCER CELLS.
12:30-13:30: Poster oral presentation session III: Presentation P33 to P48.
13:30-14:30; Lunch
14:30-16:00: Session 6: “Purines and Pyrimidines in Inflammation and
autoimmune disease”. R. T. Smolenski (Poland) and B. N. Cronstein (USA).
14:30-15:00: I-15: R.T. Smolenski (Department of Biochemistry, Medical University of Gdansk,
Gdansk, Poland). NUCLEOTIDES IN HEART VALVE DISEASE.
15:00-15:15: O-20: A. Mediero (Division of Translational Medicine, Medicine Department,
NYU School of Medicine, New York, USA). ADENOSINE A2A RECEPTOR DIMINISHES
BONE DESTRUCTION AT INFLAMED SITES, IN PART, VIA DOWNREGULATING
SEMAPHORIN4D-PLEXINB1 COMMUNICATION BETWEEN OSTEOCLASTS AND
OSTEOBLASTS.
15:15-15:30: O-21: J. Arasa (Centre of Molecular Recognition and Technological Development,
Universidad de Valencia, Valencia, Spain). BENEFICIAL EFFECT OF AN ADENOSINE A2A
RECEPTOR AGONIST ON TPA-INDUCED SKIN HYPERPLASIA.
15:30-15:45: O-22: J. Feig (Pharmacology, New York University School of Medicine, New
York, USA). TENOFOVIR, A POTENT ANTI-VIRAL AGENT, IS AN ECTO5’NUCLEOTIDASE (CD73) INHIBITOR WHICH DECREASES ADENOSINE
PRODUCTION TO PREVENT DERMAL FIBROSIS IN A MURINE MODEL OF
SCLERODERMA.
15:45-16:00: O-23: B. Kutryb (Department of Biochemistry and Clinical Physiology, Medical
University of Gdansk, Gdansk, Poland). ENZYMES OF EXTRACELLULAR NUCLEOTIDE
CATABOLISM IN AORTIC WALL AND ITS RELATION TO DEVELOPMENT OF
ATHEROSCLEROSIS IN APOE/LDLR DOUBLE KO MICE.
16:00-16:30: Coffee Break
16:30-18:00: Poster oral presentation session IV: Presentation P49 to P66.
18:00-19:00: PP SOCIETY Meeting
20:00-23:00: Symposium DINNER (“El Rocío” Restaurant)
Wednesday 12th
08:30-10:30: Session 7: “Purine and Pyrimidine analogs”. F. Bontemps (Belgium)
and L. Jordheim (France).
08:30-08:50: I-16: L. Jordheim (CRCL, INSERM U1052 / CNRS 5286, Lyon,
France).PHARMACOLOGICAL OR BIOLOGICAL INHIBITION OF 5’-NUCLEOTIDASE
CN-II SENSITIZE CANCER CELLS TO NUCLEOSIDE ANALOGUES.
08:50-09:10: O-24: S. Eriksson (Department of Anatomy, Physiology and Biochemistry, The
Swedish University of Agricultural Sciences, Uppsala, Sweden). OXIDATIVE STRESS
REGULATION OF THE DEOXYNUCLEOSIDE KINASES: IMPLICATIONS FOR
CHEMOTHERAPY WITH NUCLEOSIDE ANALOGS.
09:10- 09:30: O-25: C. Requena (Biochemistry and Molecular Pharmacology, Instituto de
Parasitología y Biomedicina Lopez-Neyra, Consejo Superior de Investigaciones Científicas
(CSIC), Armilla, Granada, Spain). DCTPP1 HYDROLYZES THE OXIDIZED NUCLEOTIDE
DERIVATIVE 5-FORMYL-DCTP AND REGULATES THE HOMEOSTASIS OF 2´DEOXYCYTIDINE-5´-TRIPHOSPHATE IN HUMAN CELLS.
09:30-09:50: O-26: P. Blaker (Gastroenterology, Guys and St Thomas Hospitals NHS
Foundation Trust, London, UK). THE MECHANISM OF ALLOPURINOL INDUCED TPMT
INHIBITION.
09:50-10:10: O-27: D. Topalis (Immunology and Microbiology, KU Leuven - Rega Institute for
Medical Research, Leuven, Belgium). IDENTIFICATION OF MUTATIONS IN THE
UMP/CMP KINASE CONFERRING CIDOFOVIR-RESISTANCE TO HPV16(+) SIHA
CELLS.
10:10-10:30: I-17: F. Bontemps (De Duve Institute, Université catholique de Louvain, Brussels,
Belgium). AN ALTERNATIVE PATTERN FOR THE P53/P21 PATHWAY IN RESPONSE TO
NUCLEOSIDE ANALOGS.
10:30-11:00: Coffee Break
11:00-12:45: Session 8: “Purine and Pyrimidine metabolism and mitochondrial
disorders”. R. Martí (Spain) and M. Hirano (USA).
11:00-11:15: I-18: M. Hirano (H. Houston Merritt Center, Department of Neurology, Columbia
University Medical Center, New York, NY, USA). BALANCED DEOXYRIBONUCLEOTIDE
TRIPHOSPHATE POOLS ARE ESSENTIAL FOR MITOCHONDRIAL DNA
MAINTENANCE.
11:15-11:30: I-19: R. Martí (Mitochondrial Disorders Unit, Vall d’Hebron Institut de Recerca
and CIBERER, Barcelona, Spain ). ROLE OF TK2 KINETICS AND REGULATION IN
THYMIDINE-INDUCED MITOCHONDRIAL DNA DEPLETION.
11:30-11:45: O-28: Y. Cámara (Mitochondrial Disorders Unit, Vall d’Hebron Institut de Recerca
and CIBERER, Barcelona, Spain). A PHARMACOLOGICAL APPROACH FOR TREATING
MITOCHONDRIAL DNA DEPLETION: NUCLEOSIDE SUPPLY AND/OR INHIBITION OF
NUCLEOSIDE CATABOLISM.
11:45-12:00: O-29: M. Levene (Clinical Sciences, St Georges University, London, UK).
ERYTHROCYTE ENCAPSULATED THYMIDINE PHOSPHOSPHORYLASE (EE-TP)
THERAPY IN MITOCHONDRIAL NEUROGASTROINTESTINAL
ENCEPHALOMYOPATHY (MNGIE).
12:00-12:15: O-30: C. Garone (Neurology, Columbia University Medical Center, New York,
USA). DEOXYPYRIMIDINE MONOPHOSPHATES TREATMENT FOR THYMIDINE
KINASE 2 DEFICIENCY.
12:15-12:30: O-31: C. Desler (Department of Cellular and Molecular Medicine, Copenhagen
University, Center for Healthy Aging, Copenhagen, Denmark). BALANCED LEVELS OF
DNTP LINKS MITOCHONDRIAL DYSFUNCTION TO CELLULAR TRANSFORMATION.
12:30-12:45: O-32: X. Zhou (Department of Laboratory medicine, Karolinska Institutet,
Stockholm, Sweden). TRANSGENE EXPRESSION OF DROSOPHILA MELANOGASTER
NUCLEOSIDE KINASE REVERSES MITOCHONDRIAL THYMIDINE KINASE 2
DEFICIENCY.
12:45-13:30: Visit to Poster Panels (session V).
13:30-14:30: Lunch
14:30-16:00: Session 9: “Non-mammalian purine and pyrimidine metabolism”. D.
González-Pacanowska (Spain) and H. de Koning (UK).
14:30- 15:00: I-20: D. González-Pacanowska (Department of Biochemistry and Molecular
Pharmacology , Instituto de Parasitología y Biomedicina, Consejo Superior de Investigaciones
Científicas , Armilla, Granada, Spain). ROLE AND FATE OF DUTP IN TRYPANOSOMA
BRUCEI.
15:00- 15:30: I-21. H. P. Koning (Institute of Infection, Immunity and Inflammation; College of
Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK).
METABOLOMIC STUDIES OF THE MECHANISM OF ACTION OF FLUORINATED
PYRIMIDINES IN KINETOPLASTID PARASITES.
15:30- 15:40: O-33: L. Wang (Department of Anatomy, Physiology and Biochemistry, Swedish
University of Agricultural Sciences, Uppsala, Sweden). MYCOPLASMA PNEUMONIAE
THYMDINE PHOSPHORYLASE.
15:40-15:50: O-34: G. Azzam (MRC Functional Genomics Unit, DPAG, University of Oxford,
Oxford, UK). ONLY ONE ISOFORM OF DROSOPHILA MELANOGASTER CTP
SYNTHASE FORMS THE CYTOOPHIDIUM.
15:50-16:00: O-35: A. Hofer (Medical Biochemistry and Biophysics, Umeå University, Sweden,
Umeå, Sweden). TARGETING THE NUCLEOTIDE METABOLISM IN TRYPANOSOMA
BRUCEI.
16:00-16:30: Coffee Break
16:30-18:30: Closing Conference “Anne Simmonds Memorial Lecture” (Prof.
Beverly Mitchell, MD, George E. Becker Professor of Medicine and Director of
Stanford Cancer Institute) and Awards
Thursday 13th
Farewell.
POSTER SESSIONS
Instructions for Poster Presentation: PP´15.
• All Posters will be presented in two ways: orally and in the poster format.
• The poster format should be posted upon arrival to the Congress venue (Hotel Velázquez,
Madrid).
• The size of the blackboard to post your poster will be 90 cm (35 inches) width and 120 cm
(47 inches) high.
• The poster should be posted during all the Congress days.
• There will be 5 Poster sessions. The first 4 Poster sessions will be chaired by two persons
each, to allow oral presentations.
• Each oral presentation should last only 3 minutes (15-18 oral presentations per session). The
person who presents the work summarized in the poster may bring 3 slides maximum for
oral presentation.
• The fifth Poster session (Wednesday, 12:45 to 13:30 h) will be devoted to select the Poster
awards and for interaction and scientific interchange among attendants. The chairs of the
first 4 Poster sessions will select 2 Posters as finalists for the Poster awards. They will visit
the 8 Posters selected, may formulate questions, and decide the best 3-4 Posters that will
receive a Poster award.
Session Poster I: Monday 10th 12:30-13:30; P1-P16.
P-1: NEW JAPANESE FAMILIES WITH THE HPRT DEFICIENCIES: HPRT MUTATIONS
AND PRPP CONCENTRATION.
Y. Yamada(1), K. Yamada(1), D. Fukushi(1), N. Wakamatsu(1), Y. Matsuda(2), T. Ueda(2), H.
Hasegawa(3), K. Ichida(3).
(1)
Genetics, Institute for Developmental Research, Aichi Human Service Center, Aichi,
Japan (2)Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui,
Japan (3)Pathophysiology, School of Pharmacy, Tokyo University of Pharmacy and Life
Sciences, Tokyo, Japan.
P-2: INHIBITING PNP FOR THE THERAPY OF HYPERURICEMIA IN LESCH-NYHAN
DISEASE: PRELIMINARY IN VITRO STUDIES WITH ANALOGUES OF IMMUCILLING.
E. Baldini, G. Jacomelli, F. Corelli, V. Micheli.
Biotecnologie Chimica e Farmacia, Università di Siena, Siena, Italy.
P-3: ABCG2 DYSFUNCTION INCREASES THE RISK OF RENAL OVERLOAD
HYPERURICEMIA.
H. Matsuo(1), T. Takada(2), A. Nakayama(1), T. Shimizu(3), M. Sakiyama(1), T. Hosoya(4), N.
Shinomiya(1), K. Ichida(5).
(1)
Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical
College, Tokorozawa(2)Department of Pharmacy, The University of Tokyo Hospital,
Tokyo(3)Gout Clinic, Midorigaoka Hospital, Takatsuki (4)Division of Kidney and Hypertension,
Department of Internal, Jikei University School of Medicine, Tokyo(5)Department of
Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo, Japan.
P-4: ABCG2 DYSFUNCTION INCREASES SERUM URIC ACID BY DECREASED
INTESTINAL URATE EXCRETION.
T. Takada(1), K. Ichida(2), H. Matsuo(3), A. Nakayama(3), K. Murakami(1), Y. Yamanashi(1), H.
Kasuga(1), H. Suzuki(1).
(1)
Department of Pharmacy, The University of Tokyo Hospital, Tokyo. (2)Department of
Pathophysiology, Tokyo University of Pharmacy and Life Sciences, Tokyo (3)Department of
Integrative Physiology and Bio-Nano Medicine, National Defense Medical College,
Tokorozawa.
P-5: DETERMINATION AND PROFILING OF PURINES IN FOODS BY USING HPLC
AND LC-MS.
K. Inazawa, Y. Kato, A. Sato, N. Yamaoka, T. Fukuuchi, K. Nakagomi, K. Kaneko.
Faculty of Pharma Sciences, Teikyo University, Tokyo, Japan.
P-6: PROTEOMIC ANALYSIS OF A GOUTY TOPHUS FROM A PATIENT WITH
RECURRENT GOUT TO EXAMINE THE ROLE OF MATRIX PROTEIN.
K. Kaneko(1), H. Iwamoto(1), M. Yasuda(1), T. Yamanobe(2), K. Inazawa(1), N. Yamaoka(1), T.
Fukuuchi(1), S. Fujimori(3).
(1)
Faculty of Pharma Sciences,(2)Laboratory of Analytical Chemistry,(3)Department of Internal
Medicine, Teikyo University, Tokyo, Japan.
P-7: PROMISING RESULTS FROM PHASE I STUDY OF LC350189 - A NOVEL
XANTHINE OXIDASE INHIBITOR FOR HYPERURICEMIA AND GOUT.
J. Seo, D. Lim.
RnD Park, LG Life Sciences, Ltd, Daejeon, South Korea.
P-8: CLINICAL CHARACTERISTICS OF THE METABOLIC SYNDROME IN PATIENTS
WITH PRIMARY GOUT.
R. Bailén Almorox(1), N. González Senac(1), T. Aparicio González(1), E. de Miguel(2), R. J.
Torres(3), J. G. Puig(1).
(1)
Metabolic-Vascular Unit, Internal Medicine,(2)Rheumatology,(3)Biochemistry, Hospital
Universitario la Paz, IdiPaz, Madrid, Spain.
P-9: POLYMORPHISMS IN RENAL URATE TRANSPORTER GENES IN GOUT PATIENTS
WITH NORMAL AND DECREASED URINARY URIC ACID EXCRETION.
R. J. Torres(3), E. de Miguel(2), R. Bailen(1), J. Banegas(4), J. G. Puig(1).
(1)
Metabolic-Vascular Unit, Internal Medicine,(2)Rheumatology,(3)Biochemistry, Hospital
Universitario la Paz, IdiPaz, Madrid, Spain. (4)Medicina Preventiva y Salud Publica, Facultad de
Medicina, Universidad Autónoma, Madrid, Spain.
P-10: FEBUXOSTAT IS USEFUL FOR THE PROPHYLAXIS AND THE TREATMENT OF
INTERMEDIATE RISK OF TUMOR LYSIS SYNDROME ASSOCIATED WITH
HEMATOLOGICAL MALIGNANCIES.
M. Takai, T. Yamauchi, K. Ooiwa, Y. Matsuda, M. Ookura, S. Kishi, A. Yashida, T. Ueda.
First Department of Internal Medicine, University of Fukui, Fukui, Japan.
P-11: RESOLUTION OF MASSIVE TOPHACEUS GOUT WITH THREE URATELOWERING DRUGS; C. Mejia-Chew(1), R. J. Torres(2), E. De Miguel(3), J. G. Puig(1).
(1)
Internal Medicine-Metabolic-Vascular Unit,(2)Biochemistry Laboratory,(3)Rheumatology,
Hospital Universitario la Paz, IdiPaz, Madrid, Spain.
P-12: HYPERURICEMIA IN HEMATOLOGICAL MALIGNANCIES IS CAUSED BY AN
INSUFFICIENT URINARY EXCRETION.
Y. Oka(1), H. Tashiro(1), R. Shirasaki(1), T. Yamamoto(1), N. Akiyama(1), K. Kawasugi(1), N.
Shirafuji(1), S. Fujimori(2).
(1)
Department of Hematology/Oncology,(2)Department of Internal Medicine, Teikyo University
School of Medicine, Tokyo, Japan.
P-13: FALSE INCREASE OF URIC ACID LEVEL OF MOUSE BLOOD IN VITRO.
M. Hosoyamada(1), T. Watanabe(2), N. Tomioka(1), M. Doshi(1), S. Watanabe(2), M. Tsuchiya(2);
(1)
Human Physiology and Pathology,(2)Practical Pharmacy, Faculty of Pharma-Sciences, Teikyo
University, Tokyo, Japan.
P-14: FALSE-NEGATIVE SCREENING FOR ADENYLOSUCCINATE LYASE
DEFICIENCY CAUSED BY DERIBOSYLATION OF THE URINARY BIOMARKERS.
J. Krijt(1), A. Jurecka(2), V. Škopová(1), S. Kmoch(1), M. Zikánová(1).
(1)
Institute of Inherited Metabolic Disorders, First Faculty of Medicine, Charles University in
Prague and General University Hospital in Prague , Prague(2)Department of Medical Genetics,
The Children’s Memorial Health Institute, Warsaw, Poland.
P-15: APRT DEFICIENCY IN AN ASIAN FAMILY.
M. Arenas(1), G. Balasubramaniam(2), M. Almond(2), E. Escuredo(1), T. Marinaki(1), L. Fairbanks(1).
(1)
Purine Research Laboratory , GSTS Pathology, St. Thomas Hospital, London(2)Renal
Department , Southend University Hospital, London, UK.
P-16: IDENTIFICATION OF A NOVEL SYNONYMOUS MUTATION IN THE HUMAN ΒUREIDOPROPIONASE GENE UPB1 AFFECTING PRE-MRNA SPLICING.
Y. Nakajima(1), J. Meijer(2), C. Zhang(3), R. Meinsma(2), T. Ito(1), A. Van Kuilenburg(2);
(1)
Neonatology and Pediatrics, Nagoya City University Medical School, Nagoya (2)Laboratory of
Genetic Metabolic Diseases, Academic Medical Center, Amsterdam (3)Research and
Development , MILS International, Kanazawa, Japan.
Session Poster II: Monday 10th 16:30-18:00; P17-P32.
P-17: IDENTIFICATION OF A HYPOURICEMIA PATIENT WITH SLC2A9 R380W, A
RHUC2 MUTATION.
T. Chiba(1), H. Matsuo(1), A. Nakayama(1), Y. Kawamura(1), M. Sakiyama(1), M. Hosoyamada(2), N.
Hamajima(3), N. Shinomiya(1).
(1)
Department of Integrative Physiology and Bio-Nano Medicine, National Defense Medical
College, Tokorozawa. (2)Department of Human Physiology and Pathology, Teikyo University
School of Pharmaceutical Sciences, Tokyo. (3)Department of Preventive Medicine/Biostatistics
and Medical, Nagoya University Graduate School of Medicine, Nagoya, Japan.
P-18: CHARACTERISATION OF 18 PATIENTS WITH RENAL HYPOURICEMIA:
BIOCHEMICAL, MOLECULAR GENETICS AND FUNCTION ANALYSIS.
B. Stiburkova(1) , I. Sebesta(2) , K. Ichida(3) , M. Nakamura (4).
(1)
Institute of Inherited Metabolic Disorders, (2) Institute of Clinical Biochemistry and
Laboratory Medicine, First Faculty of Medicine, Charles University in Prague and General
University Hospital in Prague, Czech Republic. (3) Department of Pathophysiology, Tokyo
University of Pharmacy and Life Sciences, Japan. (4) Division of Kidney and Hypertension, Jikei
University School of Medicine, Tokyo, Japan.
P-19: TOMATO THYMIDINE KINASE 1 IS POORLY TTP FEED-BACK REGULATED.
B. Munch-Petersen(1), N. Larsen(2), J. Piskur(2).
(1)
Science, Systems and Models, Roskilde University, Roskilde, Denmark. (2)Biology, Lund
University, Lund, Sweden.
P-20: THE PYRIMIDINE NUCLEOSIDE PHOSPHORYLASE OF MYCOPLASMA
HYORHINIS AND HOW IT MAY AFFECT NUCLEOSIDE-BASED THERAPY.
J. Vande Voorde(1), S. Liekens(1), F. Gago(2), J. Balzarini(1).
(1)
Rega Institute for Medical Research, KU Leuven, Leuven, Belgium(2)Departamento de
Farmacología, Universidad de Alcalá , Alcalá de Henares, Madrid, Spain.
P-21: MIR-211 HAS A PROGNOSTIC ROLE AND MODULATES GEMCITABINE
ACTIVITY THROUGH DOWNREGULATION OF RIBONUCLEOTIDE REDUCTASE IN
PANCREATIC CANCER.
M. Maftouh(1), E. Giovannetti(1), A. Avan(1), A. van der Velde(2), L. G. Leon(2), N. Funel(3), U.
Boggi(3), G. J. Peters(1).
(1)
Medical Oncology,(2)Centre Integrative Bioinformatics, VU University Medical Center,
Amsterdam (3)Surgery , University of Pisa, Pisa, Italy.
P-22: POTENTIATION OF FLUDARABINE AND CLADRIBINE CYTOTOXICITY BY
APHIDICOLIN IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS.
E. Starczewska(1), C. Smal(1), E. Van Den Neste(2), F. Bontemps(1).
(1)
de Duve Institute, Université catholique de Louvain, Brussels, Belgium(2)Department of
Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels,
Belgium.
P-23: HIGH LEVELS OF SERUM THYMIDINE KINASE 1 SUBUNIT OF 25 KDA IN
PATIENTS WITH SOLID TUMORS MAY SERVE AS BIOMARKER FOR TUMOR CELL
PROLIFERATION.
K. Kiran(1), L. Hansson(2), S. Eriksson(1).
(1)
Anatomy, Physiology, Swedish University of Agricultural Sciences, Uppsala,
Sweden (2)Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
P-24: PREDICTIVE MARKERS FOR TOXICITY AND RESPONSE TO PEMETREXED
CHEMOTHERAPY.
A. Corrigan(1), M. Arenas Hernandez(1), S. Wickramasinghe(1), T. Hoskin(1), J. Sanderson(2), J.
Spicer(3), A. Marinaki(1).
(1)
Purine Research Laboratoy, GSTS Pathology, St Thomas' Hospital, London(2)Department of
Gastroenterology,(3)Department of Medical Oncology, Guy's Hospital, London, UK.
P-25: TESTING FOR ASSOCIATION BETWEEN TPMT, COMT AND NOX3 VARIANTS
AND THE ONSET OF OTOTOXICITY IN LUNG CANCER PATIENTS TREATED WITH
PLATINUM CHEMOTHERAPY.
A. Corrigan(1), R. Lal(2), S. Wickramasinhe(1), S. Whelan(2), J. Sanderson(3), A. Marinaki(1), J.
Spicer(2).
(1)
Purine Research Laboratory, GSTS Pathology, St Thomas' Hospital, London(2)Department of
Medical Oncology,(3)Department of Gastroenterology, Guy's Hospital, London, UK.
P-26: DIFLUORODEOXYURIDINE PHOSPHORYLATION AND SUBSEQUENT DNA
INCORPORATION IN RELATION TO GEMCITABINE TREATMENT.
R. Honeywell, E. Giovannetti, I. Kathmann, G. Peters.
Medical Oncology, Vrij University Medical Center, Amsterdam, Netherlands.
P-27: RADIOSENSITIZATION BY TAS-102 IN COLORECTAL CANCER.
M. Elnaggar(1), J. van den Berg(2), I. Bijnsdorp(3), P. Sminia(2), G. J.Peters(4).
(1)
Medical Oncology, Assiut University hospital, Egypt (2)Radiation oncology,(3)Urology , VU
University Medical Center, Amsterdam, Netherlands(4)Medical oncology, VU University
Medical Center, Amsterdam, Netherlands.
P-28: CROSS-VALIDATION OF CYTIDINE DEAMINASE USING DIFFERENT BLOOD
COMPARTMENTS AND VARIOUS ASSAYS IN THREE EORTC-PHARMACOLOGY AND
MOLECULAR MECHANISM (PAMM) GROUP LABORATORIES.
G. Peters(1), E. Giovannetti(1), R. Honeywell(1), N. Losekoot(1), M. Etiennne(2), G. Milano(2), C.
Serdjebi(3), J. Ciccolini(3).
(1)
Medical Oncology, VU University Medical Center, Amsterdam, Netherlands (2)Laboratoire
d'Oncopharmacologie, Centre Antoine Lacassagne , Nice, Italy (3)Transfer Oncology Laboratory,
Aix-Marseille University, Marseille, France.
P-29: CLOFARABINE REACTIVATES DNA METHYLATION-SILENCED TUMOUR
SUPPRESSOR GENES IN BREAST CANCER CELLS.
K. Lubecka-Pietruszewska(1), A. Kaufman-Szymczyk(1), B. Stefanska(2), B. Cebula-Obrzut(3), P.
Smolewski(3), K. Fabianowska-Majewska(1).
(1)
Department of Biomedical Chemistry, Medical University of Lodz ,Lodz, Poland .
(2)
Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada.
(3)
Department of Experimental Haematology, Medical University of Lodz, Lodz, Poland.
P-30: ADENOSINE A2A RECEPTOR STIMULATION INHIBITS OSTEOCLAST
FORMATION BY SUPPRESSING NFKB TRANSLOCATION TO THE NUCLEUS BY A
PKA-ERK1/2 MEDIATED MECHANISM.
A. Mediero, B. Cronstein.
Division of Translational Medicine, Medicine Department, NYU School of Medicine, New
York, USA.
P-31: ADENOSINE A2A RECEPTOR (A2AR) IS A FINE-TUNE REGULATOR OF THE
COLLAGEN-1:COLLAGEN-3 BALANCE.
M. Perez-Aso, B. Cronstein.
Division of Translational Medicine, Department of Medicine, NYU School of Medicine, New
York, USA.
P-32: INCREASED HCNT2-RELATED RIBAVIRIN UPTAKE IN HUMAN HEPATOCYTE
HHL5 CELLS AFTER IFN-Α TREATMENT.
P. Fernández-Calotti, I. Pinilla-Macua, M. Pastor-Anglada.
Biochemistry and Molecular Biology, Institut de Biomedicina (IBUB)-University of Barcelona,
Centro de Investigación Biomédica en Red-Enfermedades Hepáticas y Digestivas (CIBER
EHD), Barcelona, Spain.
Session Poster III: Tuesday 11th 12:30-13:30; P33-P48.
P-33: SUBCELLULAR LOCALIZATION OF DEOXYRIBONUCLEOSIDE KINASES IN
INSECTS AND PLANTS.
A. Clausen(1), Z. Mutahir(1), B. Munch-Petersen(2), J. Rawls(3), J. Piskur(1).
(1)
Biology, Lund University, Lund, Sweden (2)Science, Systems and Models, Roskilde University,
Roskilde, Denmark(3)Biology, University of Kentucky, Lexington, USA.
P-34: THYMIDINE KINASE 1 REGULATORY FINE-TUNING THROUGH TETRAMER
FORMATION.
Z. Mutahir(1), A. R. Clausen(1), K. Andersson(1), S. M. Wisen(1), B. Munch-Petersen(2), J. Piskur(1);
(1)
Department of Biology, Lund University, Lund, Sweden (2)Department of Science, Systems
and Models, Roskilde University, Denmark.
P-35: DOWN REGULATION OF MITOCHONDRIAL THYMIDINE KINASE 2 AND
DEOXYGUANOSINE KINASE BY ANTIVIRAL NUCLEOSIDE ANALOGS.
R. Sun, S. Eriksson, L. Wang.
Department of Anatomy, Physiology and Biochemistry, Swedish University of Agricultural
Sciences, Uppsala, Sweden.
P-36: CHARACTERIZING SUBSTRATE PROPERTIES OF PURINE-RELATED
COMPOUNDS WITH PURINE METABOLISM ENZYMES, XANTHINE OXIDASE,
GUANINE DEAMINASE, 5'-NUCLEOTIDASE, PURINE NUCLEOSIDE
PHOSPHORYLASE, AND URATE HYDROXYLASE.
T. Fukuuchi, K. Yamamoto, A. Morimura, M. Kawatani, N. Yamaoka, K. Kaneko.
Faculty of Pharma Sciences, Teikyo University, Tokyo , Japan.
P-37: ADENOSINE KINASE INHIBITORS: IDENTIFICATION OF NEW LEAD
STRUCTURES BY VIRTUAL AND FOCUSED SCREENING.
M. Köse(1), L. Tan(2), J. Bajorath(2), A. C. Schiedel(1), C. E. Müller(1).
(1)
Pharmaceutical Chemistry I, PharmaCenter Bonn, Pharmaceutical Institute, University of
Bonn, Germany.(2)Department of Life Science Informatics, B-IT, University of Bonn, Germany .
P-38: EFFECT OF FLOW ON EXPRESSION OF ECTO-5'-NUCLEOTIDASE (E5N) AND
ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE (ENTPD) IN
ENDOTHELIAL CELLS.
E. Kaniewska(1), A. Sielicka(1), N. Mongkoldhumrongkul(2), P. Sarathchandra(2), I. PelikantMalecka, M. Olkowicz(1), E. M. Slominska(1), M. H. Yacoub, A. Chester(2), R. T. Smolenski(1);
(1)
Department of Biochemistry, Medical Univeristy of Gdansk, Gdansk, Poland (2)Heart Science
Centre, Imperial College London, Harefield, UK.
P-39: ACTIVITY OF AMP REGULATED PROTEIN KINASE (AMPK) IN THE HEART OF
DIABETIC MOUSE.
I. Rybakowska(1), P. Romaszko(2), M. Zabielska(2), M. Olkowicz(2), E. M. Slominska(2), R. T.
Smolenski(2);.
(1)
Department of Biochemistry and Clinical Physiology,(2)Department of Biochemistry, Medical
University of Gdansk, Gdansk, Poland.
P-40: EXTRACELLULAR ADENINE NUCLEOTIDE CATABOLISM IN HEART VALVES
AND ITS CHANGE IN PATHOLOGY.
M. Kapczynska(1), M. Toczek(1), B. Kutryb(1), A. Szkodo(1), M. Lipinski(1), E. M. Slominska(1), R.
Lango(2), R. T. Smolenski(1).
(1)
Department of Biochemistry,(2)Department of Cardiovascular Anesthesia, Medical University
of Gdansk, Gdansk, Poland.
P-41: EFFECT OF NITROSATIVE STRESS ON EXTRACELLULAR NUCLEOTIDE
METABOLISM IN ENDOTHELIAL CELLS.
A. Sielicka(1), I. Pelikant-Malecka(1), E. Kaniewska(1), M. Olkowicz(1), Z. Pankrac(2), M.
Swiatkowska-Freund(2), K. Preis(2), E. M. Slominska, R. T. Smolenski(1).
(1)
Department of Biochemistry,(2)Department of Perinatology and Obstetrics, Medical University
of Gdansk, Gdansk, Poland.
P-42: IN VITRO AND CELLULAR EFFECTS OF 4-PYRIDONE-3-CARBOXAMIDE
RIBOSIDE (4PYR) ON ENZYMES OF NUCLEOTIDE METABOLISM.
E. M. Slominska(1), T. Borkowski(1), I. Rybakowska(2), M. Abramowicz(1), C. Orlewska(3), R. T.
Smolenski(1).
(1)
Dept. of Biochemistry,(2)Dept. of Biochemistry and Clinical Physiology,(3)Dept. of Organic
Chemistry, Medical University of Gdansk, Gdansk, Poland.
P-43: EPAC1 ACTIVATION IS REQUIRED FOR NFKB NUCLEAR TRANSLOCATION
AND OSTEOCLAST DIFFERENTIATION.
A. Mediero, B. Cronstein.
Division of Translational Medicine, Medicine Department, NYU School of Medicine, New
York, USA.
P-44: PHARMACOLOGICAL BLOCKADE OF ADENOSINE A2A RECEPTORS (A2AR)
PREVENTS RADIATION-INDUCED DERMAL INJURY.
M. Perez-Aso(1), Y. Cheng Low(2), O. Ezeamuzie(2), J. Levine(2), B. Cronstein(1).
(1)
Dvision of Translational Medicine, Department of Medicine, (2)Department of Surgery, NYU
School of Medicine, New York, USA.
P-45: ADENOSINE A2A AND A2B RECEPTORS REGULATE KERATINOCYTE
FUNCTION;.
R. Andrés(1), J. Arasa(1), M. Payá(1), P. Navalón(2), F. Valcuende(3), M. Terencio(1), M.
Montesinos(1);
(1)
Center of Molecular Recognition and Technological Development, Universidad de Valencia,
Valencia, Spain(2)Department of Urology, Consorcio Hospital General Universitario de Valencia,
Valencia, Spain(3)Department of Dermatology, Hospital de la Plana, Villarreal, Castellón, Spain.
P-46: CHRONIC PROSTATITIS: A URATE CRYSTAL INDUCED DISEASE?.
J. Park(1), M. Roudier(2), L. Chery(3), P. Simkin(1).
(1)
Rheumatology,(2)Pathology,(3)Urology, University of Washington, Seattle, USA.
P-47: URATE CRYSTALS IN CORONARY ARTERIES.
J. Park, D. Soman, P. Simkin.
Rheumatology, University of Washington, Seattle, USA.
P-48: EFFECTS OF EXPRESSION OF ECTO-NUCLEOSIDE TRIPHOSPHATE
DIPHOSPHOHYDROLASE 1 AND/OR ECTO-5’-NUCLEOTIDASE IN HEK293T CELLS.
M. De Giorgi(1), I. Pelikant-Malecka(2), A. Sielicka(2), E. M. Slominska(2), R. Giovannoni, A.
Cinti(1), M. Lavitrano(1), R. Smolenski(2).
(1)
Dept. of Surgery and Interdisciplinary Medicine, University Milano-Bicocca, Milano,
Italy (2)Dept. of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
Session Poster IV: Tuesday 11th 16:30-18:00; P49-P66.
P-49: ROLE OF SLC22A1 POLYMORPHISMS IN THE CELLULAR HANDLING OF
ANTIVIRAL NUCLEOSIDE-DERIVED DRUGS.
C. Arimany-Nardi(1), G. Minuesa(2), T. Keller(3), H. Koepsell(3), J. Martinez-Picado(4), M. PastorAnglada(1).
(1)
Bioquímica i Biologia Molecular, Universitat de Barcelona, IBUB, CIBERehd, Barcelona,
Spain. (2)AIDS Research Instiute-IrsiCaixa, Hospital Universitari Germans Trias I Pujol de
Badalona, Badalona, Barcelona, Spain (3)Institute of Anatomy and Cell Biology, University of
Würzburg, Würzburg, Germany (4)AIDS Research Institute-IrsiCaixa,Hospital Universitari
Germans Trias i Pujol de Badalona, ICREA , Barcelona, Spain.
P-50: FLUORESCENT NUCLEOSIDE ANALOGUES AS A TOOL FOR DETERMINING
THE IN VIVO FUNCTION OF HCNT PROTEINS.
A. Claudio(1), I. Pinilla-Macua(1), C. Sancho(2), M. Lostao(2), A. Grandas(1), M. Pastor-Anglada(1).
(1)
Bioquimica i Biologia Molecular, Universitat de Barcelona, IBUB, CIBERehd, Barcelona,
Spain (2)Departamento de Ciencias de la Alimentación y Fisiología, Universidad de Navarra,
Pamplona, Navarra, Spain.
P-51: THE INFLUENCE OF GENDER AND HAEMOGLOBIN ON TPMT ACTIVITY.
P. Blaker(1), V. Kariyawasam(1), P. Irving(1), A. Marinaki(2), J. Sanderson(1). (1)Gastroenterology,
(2)
Purine Research Laboratory , Guys and St Thomas Hospitals NHS Foundation Trust , London,
UK.
P-52: DEMETHYLATION OF METHYLMERCAPTOPURINE BY HUMAN LIVER
MICROSOMES; A ROLE FOR CYP1A2 AND CYP2C9.
P. Blaker(1), M. Smith(1), M. Arenas-Hernandez(2), L. Fairbanks(2), P. Irving(1), J. Sanderson(1), A.
Marinaki(2).
(1)
Gastroenterology,(2)Purine Research Laboratory . Guys and St Thomas Hospitals NHS
Foundation Trust, London, UK.
P-53: THYMIDINE KINASE 2 DEFICIENCY AFFECTS THE POOL OF PROLIFERATING
MYOGENIC PROGENITOR CELLS IN MICE POSTNATAL SKELETAL MUSCLE.
J. Paredes(1), X. Zhou(1), S. Höglund(2), A. Karlsson(1).
(1)
Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden(2)Department of
Chemistry - BMC , Uppsala University, Uppsala, Sweden.
P-54: GENE THERAPY USING AN AAV2/8 VECTOR CORRECTS THE BIOCHEMICAL
IMBALANCES IN A MURINE MODEL OF MNGIE.
J. Torres-Torronteras(1), C. Viscomi(2), R. Cabrera(1), Y. Cámara(1), I. Di Meo(2), M. Hirano(3), M.
Zeviani(4), R. Martí(1).
(1)
Mitochondrial Disorders Unit, Vall d’Hebron Institut de Recerca and CIBERER, Barcelona,
Spain.(2)Molecular Neurogenetics Unit, IRCCS Foundation Neurological Institute “C. Besta” .
Milano, Italy. (3)Department of Neurology, Columbia University Medical Center, New York,
USA. (4)Molecular Neurogenetics Unit, IRCCS Foundation Neurological Institute “C. Besta”,
Milano,Italy and MRC-Mitochondrial Biology Unit, Cambridge (UK).
P-55: DEVELOPMENT OF A GENE THERAPY APPROACH FOR MNGIE USING
KERATINOCYTES AS TARGET CELLS.
R. Cabrera(1), J. Torres-Torronteras(1), J. Lezcano(2), A. Holguín(2), M. del Río(2), J. Barquinero(3),
F. Larcher(2), R. Martí(1).
(1)
Mitochondrial Disorders Unit, Vall d’Hebron Institut de Recerca (VHIR) and CIBERER,
Barcelona, Spain(2)División de Biomedicina Epitelial, Centro de Investigaciones Energéticas,
Medioambientales y Tecnológicas (CIEMAT) and CIBERER, Madrid, Spain.(3)Cell and Gene
Therapy Unit, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain.
P-56: EXOGENOUS THYMIDINE AND DEOXYURIDINE EXACERBATE THE
MITOCHONDRIAL PHENOTYPE IN THYMIDINE PHOSPHORYLASE-DEFICIENT
MICE.
B. Garcia-Diaz(1), C. Garone(1), H. Mojahed(2), P. Gutierrez(1), F. Arias-Mendoza(3), M. Hirano(1).
(1)
Neurology,(3)Radiology, Columbia University Medical Center, New York, USA (2)Biomedical
Engineering , Columbia University, New York, USA.
P-57: EFFECTS OF THE SUPPLY OF DEOXYADENOSINE, DEOXYGUANOSINE AND
THEIR MONOPHOSPHATES IN DEOXYGUANOSINE KINASE DEFICIENCY:
BIOCHEMICAL CHARACTERIZATION IN CELL CULTURE.
M. Scarpelli(1), Y. Cámara(2), E. González-Vioque(2), J. Torres-Torronteras(2), A. Caballero(2), R.
Martí(2).
(1)
Mitochondrial Disorders Unit, Vall d’Hebron Institut de Recerca (Barcelona, Spain) and
Clinical Neurology, Dept of Neurological, Neuropsychological, Morphological and Movement
Sciences, University of Verona (Italy)(2)Mitochondrial Disorders Unit, Vall d’Hebron Institut de
Recerca and CIBERER, Barcelona, Spain.
P-58: NUCLEOSIDE-INDUCED ATP REDUCTION IN CELL CULTURE SUGGESTS
INCREASED ENERGY CONSUMPTION IN MITOCHONDRIAL
NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY.
M. Scarpelli(1), J. Torres-Torronteras(2), Y. Cámara(2), R. Martí(2).
(1)
Mitochondrial Disorders Unit, Vall d’Hebron Institut de Recerca (Barcelona) and Clinical
Neurology, Dept of Neurological, Neuropsychological, Morphological and Movement Sciences,
University of Verona (Italy)(2)Mitochondrial Disorders Unit, Vall d’Hebron Institut de Recerca
and CIBERER, Barcelona, Spain.
P-59: TRYPANOSOMA BRUCEI IS SENSITIVE TO CLEAVAGE-RESISTANT SUBSTRATE
ANALOGS OF ADENOSINE KINASE.
F. Ranjbarian, M. Vodnala, A. Hofer.
Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden.
P-60: SUBCELLULAR LOCALIZATION OF DEOXYRIBONUCLEOSIDE KINASES IN
INSECTS AND PLANTS; A. Clausen(1), Z. Mutahir(1), B. Munch-Petersen(2), J. Rawls(3), J.
Piskur(1).
(1)
Biology, Lund University, Lund, Sweden (2)Science, Systems and Models, Roskilde University,
Roskilde, Denmark(3)Biology. University of Kentucky, Lexington, USA.
P-61: PSEUDOMONAS AERUGINOSA CLASS IA RIBONUCLEOTIDE REDUCTASE
REPRESENTS A NEW MECHANISM OF OVERALL ACTIVITY REGULATION.
V. Rao Jonna(1), R. Rofougaran(1), M. Crona(2), B. Sjöberg(2), A. Hofer(1).
(1)
Medical Biochemistry and Biophysics, Umeå University, Umeå, Sweden. (2)Molecular Biology
and Functional Genomics, Stockholm University . Stockholm, Sweden.
P-62: AN ANTIBACTERIAL PEPTIDE SHOWED INCREASED TOXICITY TO BACTERIA
WITH DISBALANCED NUCLEOTIDE POOLS.
L. Christiansen, M. Lauridsen, B. Munch-Petersen.
Science, Systems and Models, Roskilde University, Roskilde, Denmark.
P-63: EXPRESSION, PURIFICATION AND PRELIMINARY CRYSTALLIZATION
STUDIES OF THE TOXOPLASMA GONDII DIHYDROOROTATE DEHYDROGENASE.
D. Cajiao(1), S. Ramón-Maiques(2), B. H. Zimmermann(1).
(1)
Biological Sciences Department , Universidad de los Andes, Bogotá, Colombia. (2)Structural
Bases of Genome Integrity Group, Centro Nacional de Investigaciones Oncológicas, Madrid,
Spain.
P-64: TEMPERATURE-DEPENDENT RELEASE OF ATP FROM HUMAN
ERYTHROCYTES: IN VIVO AND IN VITRO EVIDENCE.
K. Kalsi, S. Chiesa, S. Trangmar, J. Gonzalez-Alonso.
Centre for Sports Medicine and Human Performance, Brunel University, London, UK.
P-65: EFFECT OF 4-PYRIDONE-3-CARBOXAMIDE RIBONUCLEOSIDE (4PYR) POTENTIAL CARDIOVASCULAR TOXIN IN PERFUSED RAT HEART.
P. Romaszko, E. M. Slominska, R. T. Smolenski.
Department of Biochemistry, Medical University of Gdansk, Gdansk, Poland.
P-66: 4-PYRIDONE-3-CARBOXAMIDE-1Β-D-RIBONUCLEOSIDE (4PYR) METABOLISM
IN STEM CELLS AND ITS COMPARISON TO ENDOTHELIAL AND CANCER CELLS.
I. Pelikant-Malecka(1), A. Sielicka(1), E. Kaniewska(1), Z. Pankrac(2), M. Swiatkowska-Freund(2),
K. Preis(2), R. T. Smolenski(1), E. M. Slominska(1).
(1)
Department of Biochemistry,(2)Department of Perinatology and Obstetrics, Medical University
of Gdansk , Gdansk, Poland.